ДСТУ ISO 11615:2018 Інформатика в галузі охорони здоров’я. Ідентифікація лікарських засобів. Елементи і структури даних для унікальної ідентифікації та обміну регламентованою інформацією про лікарські засоби...

Даний документ доступний у тарифі «ВСЕ ВРАХОВАНО»

У Вас є питання стосовно документа? Ми раді на них відповісти!Перелік безкоштовних документівПомітили помилку в документі або на сайті? Будь ласка, напишіть нам про це!Залишити заявку на документ


ДСТУ ISO 11615:2018
(ISO 11615:2017, IDT)

Інформатика в галузі охорони здоров’я. Ідентифікація лікарських засобів. Елементи і структури даних для унікальної ідентифікації та обміну регламентованою інформацією про лікарські засоби




 
     
 
     
Не є офіційним виданням.
Офіційне видання розповсюджує національний орган стандартизації
(ДП «УкрНДНЦ» http://uas.gov.ua)

Contents

Foreword

Introduction

1 Scope

2 Normative references

3 Terms, definitions and abbreviated terms

4 Message exchange format

5 Conformance terminology and context as it relates to the ISO IDMP standards and corresponding IDMP technical specifications

6 Concepts required for the unique identification of Medicinal Products

6.1 General considerations

6.2 Authorised Medicinal Products

6.3 Investigational Medicinal Products

6.4 Concepts required for the unique identification of a Medicinal Product and the association with PhPID(s)

6.5 Concepts required for the unique identification of Medicinal Products and the association with the marketing authorisation number

6.6 Concepts required for the unique identification of Medicinal Products and the association with data carrier identifiers

7 Description of the information modelling principles and practices

7.1 General considerations

7.2 Conceptual overview diagrams

7.3 High-level diagrams

7.4 Detailed description diagrams

7.4.1 General

7.4.2 Relationships between classes

7.4.3 Attributes of classes

7.4.4 Generalised classes and patterns

7.4.5 Translation and language

8 Identifying characteristics for authorised Medicinal Products

8.1 Primary identifiers — General considerations

8.2 Medicinal Product Identifier (MPID)

8.2.1 General considerations

8.2.2 MPID code segments

8.3 Packaged Medicinal Product Identifier (PCID)

8.3.1 General considerations

8.3.2 Package description (PCID) code segment

8.4 Medicinal Product Batch Identifier (BAID1)

8.5 Medicinal Product Batch Identifier (BAID2)

9 Information for an authorised Medicinal Product

9.1 Authorised Medicinal Product — Information overview

9.1.1 General

9.1.2 Medicinal Product

9.1.3 Medicinal Product name

9.1.4 Header

9.1.5 Manufacturer/Establishment (organisation)

9.1.6 Marketing authorisation

9.1.7 Packaged Medicinal Product

9.1.8 Pharmaceutical product

9.1.9 Ingredient

9.1.10 Clinical particulars

9.2 Medicinal Product

9.2.1 General

9.2.2 Detailed description of Medicinal Product information

9.3 Marketing authorisation

9.3.1 General

9.3.2 Detailed description of marketing authorisation information

9.4 Organisation

9.4.1 General

9.4.2 Detailed description of organisation information

9.5 Manufacturer/Establishment (organisation)

9.5.1 General

9.5.2 Detailed description of manufacturer/establishment (organisation) information

9.6 Packaged Medicinal Product, including manufactured item and device

9.6.1 General

9.6.2 Detailed description of Packaged Medicinal Product information

9.7 Ingredient, substance and strength

9.7.1 General

9.7.2 Detailed description of ingredients, substance and strengthinformation

9.8 Pharmaceutical product and device

9.8.1 General

9.8.2 Detailed description of pharmaceutical product and deviceinformation

9.9 Clinical particulars

9.9.1 General

9.9.2 Detailed description for clinical particulars information

10 Identifying characteristics for Investigational Medicinal Products

10.1 General

10.2 Primary identifiers

10.2.1 General considerations

10.3 Investigational Medicinal Product Identifier (IMPID)

10.3.1 General considerations

10.3.2 IMPID code segments

10.4 Investigational Medicinal Product Package Identifier (IPCID)

10.4.1 General provisions

10.4.2 Package description code segment

10.5 Investigational Medicinal Product Batch Identifier (BAID1)

10.6 Investigational Medicinal Product Batch Identifier (BAID2)

11 Information for an Investigational Medicinal Product

11.1 General

11.2 Conceptual overview of the information for an Investigational Medicinal Product

11.2.1 General

11.2.2 Investigational Medicinal Product

11.2.3 Investigational Medicinal Product name

11.2.4 Header

11.2.5 Manufacturer/Establishment (organisation)

11.2.6 Clinical trial authorisation

11.2.7 Investigational Packaged Medicinal Product

11.2.8 Pharmaceutical product

11.2.9 Ingredient

11.2.10 Clinical particulars

11.3 Investigational Medicinal Product

11.3.1 General

11.3.2 Detailed description of Investigational Medicinal Product information

11.4 Clinical trial authorisation

11.4.1 General

11.4.2 Detailed description of clinical trial authorisation information

1.5 Manufacturer/Establishment (organisation)

11.6 Investigational Packaged Medicinal Product

11.7 Pharmaceutical product

11.7.1 General

11.7.2 Pharmaceutical product

11.7.3 Dosing and route of administration

11.8 Ingredient

11.9 Clinical particulars

11.10 PhPID sets

11.11 Device nomenclature

11.12 Device batch identifier

11.13 Physical characteristics

11.14 Other characteristics

Annex A (normative) Full model — Authorised Medicinal Products detailed diagram

Annex В (normative) Full model — Investigational Medicinal Products detailed diagram

Bibliography

Повна версія документа доступна в тарифі «ВСЕ ВРАХОВАНО».

Увійти в Особистий кабінет Детальніше про тарифи

БУДСТАНДАРТ Online